What is NeuroField?

The use of energy to address human ailments has been a source of exploration for centuries beginning with the use of electric eels, to the use of static electricity, to various forms of magnetic therapies that used stones, ore, and the laying of hands to heal those afflicted with various illnesses (Kellaway, 1946; Payne, 1990; Quinn & Strelkauskas, 1993; Quinn, 1984, 1992; Krieger, 1975). In the past 30 years there have been many different types of energy techniques offered as a form of valid therapy. One of these modalities is known as transcranial magnetic stimulation, or TMS.

TMS was originally developed by Anthony Barker at the University of Sheffield in 1985. Barker demonstrated an evoked motor response (thumb movement) by applying an electromagnetic stimulation (EMF of 1-2 Tesla) over the motor cortex of humans (Barker, Jalinous, & Freeston, 1985). As the technology evolved it became possible to give multiple pulses to people which gave rise to repetitive or rTMS. Since that time a great deal of research has been conducted strongly suggesting that rTMS has clinical value for the treatment of depression and other psychiatric conditions (Pascual-Leone et al., 1999; Arns, M., Spronk, D., & Fitzgerald, P. B. (2010); Avery, D. H., Holtzheimer, P. E., Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., et al.(2006); Brakemeier, E. L., Wilbertz, G., Rodax, S., Danker-Hopfe, H., Zinka, B., Zwanzger, P.,et al. (2008). Furthermore, rTMS has been deemed safe by the FDA and was approved for the treatment of depression in 2008.

rTMS protocols are known as either being high frequency (HF-rTMS, EMF stimulation 5Hz or greater) or low frequency (LF-rTMS, EMF stimulation 1 Hz or less). The EMF frequency and site of stimulation is theorized to have clinical effects that can have either an excitatory or inhibitory impact on neuronal cellular activity. However, due to the high intensity EMF, giving stimulation faster than 20-30 Hz at intensities >1 tesla for long durations can result in the generation of heat which can damage tissue. As a result rTMS protocols are typically given in short pulses with an ‘on’ and ‘off’ time that prevents tissue damage, but limits the frequency range in which the therapy can be given. The safety of rTMS therapy was deemed safe by the FDA in 2008 and approved for the treatment of depression in the United States.

The notion that low intensity electromagnetic stimulation could be of clinical value was one of the driving forces behind the development of the NeuroField technology. The NeuroField X2000 is a four channel frequency generator that is capable of generating a low intensity electromagnetic pulse ranging from 1-3 milligauss which is 10,000,000 times weaker than a pulse given by rTMS devices. Since the output of NeuroField is so low, it is possible to give EMF stimulation faster than 20-30 Hz, at long durations, without the concern of generating heat thereby causing tissue damage. As a result the X2000 can generate frequencies ranging from 0.31 Hz to 300,000 Hz. Lastly, the X2000 has two channels of EEG and HRV measurement capabilities. The device can give a low intensity stimulation and then immediately measure EEG and/or HRV. The EMF stimulation does not occur while the EEG or HRV are active allowing for immediate measurements that are not contaminated by the stimulation.

The NeuroField system was initially evaluated by 10 beta testers around the United States. All of which are licensed health care professionals. Dr. Dogris has written well over 50 experimental protocols for the system that have been rated by NeuroField users as having clinical value. The inflammation reduction protocol has been given the highest ratings with more than 30 NeuroField users confirming observed inflammation reduction in their clients. This technology is experimental and is currently being evaluated by licensed health care professionals. The clinical use of NeuroField is for stress reduction and relaxation. NeuroField is not available to the general public and requires a professional license to obtain at this time. NeuroField, Inc. is in the process of obtaining FDA 510K registration.

Here are some screenshots of the most recent build of our new application!


	[ Products ] [ Shipping ] [ Returns ] [ Management ]				Products What is NeuroField? The use of energy to address human ailments has been a source of exploration for centuries beginning with the use of electric eels, to the use of static electricity, to various forms of magnetic therapies that used stones, ore, and the laying of hands to heal those afflicted with various illnesses (Kellaway, 1946; Payne, 1990; Quinn & Strelkauskas, 1993; Quinn, 1984, 1992; Krieger, 1975). In the past 30 years there have been many different types of energy techniques offered as a form of valid therapy. One of these modalities is known as transcranial magnetic stimulation, or TMS. TMS was originally developed by Anthony Barker at the University of Sheffield in 1985. Barker demonstrated an evoked motor response (thumb movement) by applying an electromagnetic stimulation (EMF of 1-2 Tesla) over the motor cortex of humans (Barker, Jalinous, & Freeston, 1985). As the technology evolved it became possible to give multiple pulses to people which gave rise to repetitive or rTMS. Since that time a great deal of research has been conducted strongly suggesting that rTMS has clinical value for the treatment of depression and other psychiatric conditions (Pascual-Leone et al., 1999; Arns, M., Spronk, D., & Fitzgerald, P. B. (2010); Avery, D. H., Holtzheimer, P. E., Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., et al.(2006); Brakemeier, E. L., Wilbertz, G., Rodax, S., Danker-Hopfe, H., Zinka, B., Zwanzger, P.,et al. (2008). Furthermore, rTMS has been deemed safe by the FDA and was approved for the treatment of depression in 2008. rTMS protocols are known as either being high frequency (HF-rTMS, EMF stimulation 5Hz or greater) or low frequency (LF-rTMS, EMF stimulation 1 Hz or less). The EMF frequency and site of stimulation is theorized to have clinical effects that can have either an excitatory or inhibitory impact on neuronal cellular activity. However, due to the high intensity EMF, giving stimulation faster than 20-30 Hz at intensities >1 tesla for long durations can result in the generation of heat which can damage tissue. As a result rTMS protocols are typically given in short pulses with an ‘on’ and ‘off’ time that prevents tissue damage, but limits the frequency range in which the therapy can be given. The safety of rTMS therapy was deemed safe by the FDA in 2008 and approved for the treatment of depression in the United States. The notion that low intensity electromagnetic stimulation could be of clinical value was one of the driving forces behind the development of the NeuroField technology. The NeuroField X2000 is a four channel frequency generator that is capable of generating a low intensity electromagnetic pulse ranging from 1-3 *milligauss* which is 10,000,000 times weaker than a pulse given by rTMS devices. Since the output of NeuroField is so low, it is possible to give EMF stimulation faster than 20-30 Hz, at long durations, without the concern of generating heat thereby causing tissue damage. As a result the X2000 can generate frequencies ranging from 0.31 Hz to 300,000 Hz. Lastly, the X2000 has two channels of EEG and HRV measurement capabilities. The device can give a low intensity stimulation and then immediately measure EEG and/or HRV. The EMF stimulation does not occur while the EEG or HRV are active allowing for immediate measurements that are not contaminated by the stimulation. The NeuroField system was initially evaluated by 10 beta testers around the United States. All of which are licensed health care professionals. Dr. Dogris has written well over 50 experimental protocols for the system that have been rated by NeuroField users as having clinical value. The inflammation reduction protocol has been given the highest ratings with more than 30 NeuroField users confirming observed inflammation reduction in their clients. This technology is experimental and is currently being evaluated by licensed health care professionals. The clinical use of NeuroField is for stress reduction and relaxation. NeuroField is not available to the general public and requires a professional license to obtain at this time. NeuroField, Inc. is in the process of obtaining FDA 510K registration. Here are some screenshots of the most recent build of our new application! Top

Username:
Password:

Products

What is NeuroField?